نتائج البحث - "Carl Zuelke"

المساهمون: Schnitzbauer A.A., Zuelke C., Graeb C., Rochon J., Bilbao I., Burra P., de Jong K.P., Duvoux C., Kneteman N.M., Adam R., Bechstein W.O., Becker T., Beckebaum S., Chazouillères O., Cillo U., Colledan M., Fändrich F., Gugenheim J., Hauss J.P., Heise M., Hidalgo E., Jamieson N., Königsrainer A., Lamby P.E., Lerut J.P., Mäkisalo H., Margreiter R., Mazzaferro V., Mutzbauer I., Otto G., Pageaux G.P., Pinna A.D., Pirenne J., Rizell M., Rossi G., Rostaing L., Roy A., Turrion V.S., Schmidt J., Troisi R.I., van Hoek B., Valente U., Wolf P., Wolters H., Mirza D.F., Scholz T., Steininger R., Soderdahl G., Strasser S.I., Jauch K.W., Neuhaus P., Schlitt H.J., Geissler E.K., Schnitzbauer, A, Zuelke, C, Graeb, C, Rochon, J, Bilbao, I, Burra, P, de Jong, K, Duvoux, C, Kneteman, N, Adam, R, Bechstein, W, Becker, T, Beckebaum, S, Chazouilleres, O, Cillo, U, Colledan, M, Fandrich, F, Gugenheim, J, Hauss, J, Heise, M, Hidalgo, E, Jamieson, N, Konigsrainer, A, Lamby, P, Lerut, J, Makisalo, H, Margreiter, R, Mazzaferro, V, Mutzbauer, I, Otto, G, Pageaux, G, Pinna, A, Pirenne, J, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Turrion, V, Schmidt, J, Troisi, R, van Hoek, B, Valente, U, Wolf, P, Wolters, H, Mirza, D, Scholz, T, Steininger, R, Soderdahl, G, Strasser, S, Jauch, K, Neuhaus, P, Schlitt, H, Geissler, E, IV kirurgian klinikka, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale

المصدر: BMC Cancer, Vol 10, Iss 1, p 190 (2010)
BMC Cancer, 10
BMC CANCER
BMC Cancer, 10:190. BMC
BMC Cancer
BMC Cancer, Vol. 10, no. 190, p. [1-8] (2010)

مصطلحات موضوعية: Oncology, Cancer Research, Time Factors, medicine.medical_treatment, Medizin, Intracellular Signaling Peptides and Proteins - antagonists & inhibitors, metabolism, Kaplan-Meier Estimate, 312 Clinical medicine, Protein-Serine-Threonine Kinase, Liver transplantation, THERAPY, Study Protocol, Immunosuppressive Agent, endothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model, 0302 clinical medicine, RENAL-CELL CARCINOMA, Risk Factors, Recurrence, Surgical oncology, Medicine and Health Sciences, Liver Neoplasms - drug therapy, enzymology, mortality, surgery, Sirolimu, Prospective Studies, TUMOR PROGRESSION, Transplantation, Homologou, education.field_of_study, liver transplantation, TOR Serine-Threonine Kinases, Liver Neoplasms, Intracellular Signaling Peptides and Proteins, Immunosuppression, hepatocellular carcinoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, CANCER, 3. Good health, Europe, Multicenter Study, Treatment Outcome, TARGET, sirolimus, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Randomized Controlled Trial, mTOR, Carcinoma, Hepatocellular - drug therapy, enzymology, mortality, surgery, 030211 gastroenterology & hepatology, Immunosuppressive Agents, RCT, Human, medicine.drug, Canada, medicine.medical_specialty, Carcinoma, Hepatocellular, Time Factor, education, Population, Liver Transplantation - adverse effects, mortality, Protein Serine-Threonine Kinases, lcsh:RC254-282, Disease-Free Survival, 03 medical and health sciences, Internal medicine, Genetics, medicine, Transplantation, Homologous, Humans, Comparative Study, Rapamycin, ddc:610, Protein-Serine-Threonine Kinases - antagonists & inhibitors, metabolism, Kaplan-Meiers Estimate, business.industry, Risk Factor, Australia, Immunosuppressive Agents - therapeutic use, Sirolimus - therapeutic use, EFFICACY, Liver Transplantation, Hepatocellular Carcinoma, Sirolimus, medicine.disease, Surgery, MODEL, Transplantation, Clinical trial, Prospective Studie, Intracellular Signaling Peptides and Protein, ENDOTHELIAL GROWTH-FACTOR, CYCLOSPORINE, RAPAMYCIN, business